Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
3(33%)
Results Posted
40%(2 trials)

Phase Distribution

Ph phase_1
4
44%
Ph phase_2
1
11%
Ph phase_3
3
33%

Phase Distribution

4

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
4(50.0%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
3(37.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

9

all time

Status Distribution
Active(3)
Completed(5)
Other(1)

Detailed Status

Completed5
Recruiting2
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (50.0%)
Phase 21 (12.5%)
Phase 33 (37.5%)

Trials by Status

active_not_recruiting111%
recruiting222%
unknown111%
completed556%

Recent Activity

3 active trials
Showing 5 of 9
recruitingphase_3

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

NCT07136012
recruitingphase_3

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

NCT07293260
completedphase_2

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

NCT04270760
active_not_recruitingphase_3

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303
completedphase_1

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

NCT05489614
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07136012Phase 3

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

Recruiting
NCT07293260Phase 3

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

Recruiting
NCT04270760Phase 2

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

Completed
NCT05581303Phase 3

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

Active Not Recruiting
NCT05489614Phase 1

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

Completed
NCT06411860Phase 1

A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants

Completed
NCT05481411Phase 1

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

Completed
NCT07079267

Olpasiran Expanded Access Program

Unknown
NCT04987320Phase 1

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9